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Introduction {#sec1}
============

The molecular machinery that installs and removes post-translational modifications of chromatin has been the subject of increasing research interest not least because these protein complexes are key regulators of gene expression, but they are also promising drug targets for the epigenetic treatment of cancer and other diseases ([@bib10], [@bib16], [@bib30], [@bib38]). It is now well established that acetylation and methylation of lysine residues within the tails of histone proteins not only control the recruitment of regulatory factors but also influence the architecture of chromatin itself. The CoREST complex is one of seven families of class I histone deacetylase complexes that have specialized physiological functions but are all thought to act as repressors of gene expression. CoREST is unique within these complexes in that it removes both acetyl and methyl modifications through the activity of its demethylase (LSD1) and deacetylase (HDAC1) enzymes.

The CoREST complex was initially identified as a cofactor of the REST/NRSF (RE1-silencing transcription factor/neural-restrictive silencer factor) transcriptional repressor, which plays important roles in regulating neuron-specific gene expression and stem cell fate and development ([@bib2], [@bib4], [@bib14], [@bib46]). The core of the CoREST complex contains two histone modification enzymes, including histone deacetylase 1 or 2 ([@bib18], [@bib53]), lysine specific demethylase LSD1 ([@bib24], [@bib41], [@bib42]), and RCOR1, 2, or 3 that links the two enzymes. The classic enzymatic target for the CoREST complex is the histone H3 tail in which K4 is mono- or di-methylated and K9 is acetylated. Removal of these activating marks results in transcriptional repression ([@bib2], [@bib23], [@bib24], [@bib53]).

The RCOR protein serves as a scaffold for complex assembly and the recruitment of the complex to the repressive transcription factors ([@bib18], [@bib39], [@bib42], [@bib53]). RCOR contains an ELM2-SANT1 domain that mediates interaction with the catalytic domain of HDAC1 ([@bib53]) and a LINKER-SANT2 domain that interacts with the TOWER domain of LSD1 ([@bib42]; [Figure 1](#fig1){ref-type="fig"}A). The RCOR-SANT2 domain has also been proposed to directly interact with nucleosomal DNA ([@bib35], [@bib51]).Figure 1The CoREST Complex Forms a Stable, Enzymatically Active, and Stoichiometric Complex(A) Schematic representation of domain structures of LSD1/KDM1A/AOF2, CoREST/RCOR1, and HDAC1. Gray boxes represent the structured domains. Dashed lines indicate the interacting regions within the complex.(B) Co-expression and purification of the LSD1:RCOR1:HDAC1 ternary complex.(C) Sequence alignment of the ELM2 domain from RCOR1--3 and MTA1--3 proteins. Identical residues are shown in red, and conserved residues are shown in orange. The predicted secondary structure of RCOR1 is indicated above the sequence (green), and the secondary structure of MTA1 observed in the crystal structure is indicated below the sequence (yellow).(D) Stoichiometry/molecular weight determination of the CoREST ternary complex by SEC-MALS.(E) Deacetylase activity of the ternary complex. As expected, the activity is enhanced by 100 μM Ins(1,4,5,6)P~4~ (InsP~4~) and by Ins(1,2, 3,4,5,6)P~6~ (InsP~6~). The activity is inhibited by SAHA and MS275 (5 μM). The activity is normalized (100%) to the basal HDAC activity. The basal activity of the assay with no complex has been subtracted. Error bars indicate the SEM (n = 3). p values are shown in the form: ^∗∗∗^ p \< 0.001 or ^∗∗∗∗^ p \< 0.0001.(F) Demethylase activity of the ternary complex. As expected, the activity is inhibited by 2-PCPA and SP2509 (10 μM). The activity is normalized (100%) to the basal demethylase activity. The basal activity of the assay with no complex has been subtracted. Error bars indicate the SEM (n = 3). p values are shown in the form: ^∗∗∗^ p \< 0.001 or ^∗∗∗∗^ p \< 0.0001.

Multiple crystal structures of LSD1 in complex with the LINKER-SANT2 of RCOR have revealed the mode of assembly and the nature of the LSD1 active site and its interaction with substrates and inhibitors ([@bib7], [@bib13], [@bib51], [@bib52]). There is no structure of HDAC1 in complex with RCOR, but a homologous structure of HDAC1 bound to the ELM2-SANT domain of MTA1 likely has many features in common ([@bib29]).

Given the dual functionality of the CoREST complex, we sought to investigate the relationship between the two different enzymes when assembled together. Such an integrated understanding of the ternary complex has, to date, been lacking. We have taken a structural approach to understand the relative positioning of the two enzymes in the complex and an enzymatic approach to explore potential crosstalk between the two activities. We have found that, although the two enzymes are positioned at either ends of the complex, there is a remarkable coupling between their enzymatic activities. Inhibitors of one enzyme strongly influence the kinetics of the partner enzyme, and only one active site can engage substrate at any one time. It is also apparent that the complex exists in at least two distinct states. Exchange between these is sensitive to modulators of the complex. Finally, the structure of CoREST in complex with a nucleosome, in which histone H3K4 is modified with a propargyl inhibitor, reveals a mode of binding that is distinct from previous models.

Results {#sec2}
=======

RCOR1, LSD1, and HDAC1 Form a Stable, Enzymatically Active, Stoichiometric Ternary Complex {#sec2.1}
------------------------------------------------------------------------------------------

Studies of the CoREST complex to date have investigated the independent activities of the demethylase and deacetylase enzymes. To understand the behavior of these enzymes in the context of the full ternary CoREST complex, we have co-expressed full-length LSD1 and HDAC1 and a construct of the RCOR1 corepressor (amino acids \[aas\] 86--485) lacking only the N-terminal disordered region. The holo CoREST ternary complex was purified to homogeneity using an N-terminal FLAG affinity tag followed by size exclusion chromatography ([Figure 1](#fig1){ref-type="fig"}B).

In our previous studies, we have observed that corepressor complexes containing class I HDACs (SMRT/NCoR, NuRD, and MiDAC) assemble into either dimeric or tetrameric complexes ([@bib20], [@bib29], [@bib31]). Detailed structural information is available for the crystal structure of the dimeric MTA1:HDAC1 complex ([@bib29])---see alignment ([Figure 1](#fig1){ref-type="fig"}C). To determine the oligomerization state of the CoREST complex, we used size exclusion chromatography coupled with multi-angle light scattering (SEC-MALS). The overall molecular weight was measured to be ∼200 kDa ([Figure 1](#fig1){ref-type="fig"}D), which correlates with the predicted monomeric molecular weight of 193 kDa (full-length LSD1, 92.9 kDa; full-length HDAC1, 55.1 kDa; RCOR1~86--485~, 45.1 kDa), indicating that the full ternary CoREST complex contains a single copy of HDAC1, LSD1, and RCOR1. A sequence comparison of RCOR1--3 with MTA1--3 shows that the ELM2 domain within RCOR1 lacks the helices that mediate dimerization of MTA1 in the NuRD corepressor complex ([Figure 1](#fig1){ref-type="fig"}C).

To confirm that the ternary complex that we expressed and purified from HEK293 cells is active, we used fluorogenic enzyme assays to measure both the deacetylase and demethylase activity of the complex ([Figures 1](#fig1){ref-type="fig"}E and 1F). As controls, we used the HDAC inhibitors SAHA and MS275 and the demethylase inhibitors 2-PCPA and SP2509 to confirm that the observed activity could be inhibited as expected. Several class I HDAC complexes are activated by inositol phosphates that bind in a pocket between the corepressor and the HDAC, close to the active site ([@bib20], [@bib29], [@bib47], [@bib48]). Inspection of the sequence of RCOR1 suggests that the inositol phosphate binding residues are conserved, and therefore, we would predict that the CoREST complex would also interact with inositol phosphates ([Figure S1](#mmc1){ref-type="supplementary-material"}A). To test this, we measured the deacetylase activity of the ternary complexes in the absence and presence of Ins(1,4,5,6)P~4~ and InsP~6~. We observed a significant increase in HDAC activity in the presence of both inositol phosphates, suggesting that these may regulate the HDAC activity of the CoREST complex ([Figure 1](#fig1){ref-type="fig"}E). As for other class I HDAC complexes, Ins(1,3,4,5,6)P~5~ also activates HDAC1 in the CoREST complex ([Figure S1](#mmc1){ref-type="supplementary-material"}B; [@bib48]).

Coupled Kinetics of the LSD1 and HDAC1 Enzymes within the CoREST Complex {#sec2.2}
------------------------------------------------------------------------

To determine whether the LSD1 and HDAC1 enzymes within the CoREST complex behave as independent enzymes or whether they are coupled, a ^1^H NMR-based assay was developed. In this assay, demethylation and deacetylation of 21-amino-acid synthetic peptides corresponding to the N terminus of histone H3 (with specific post-translational modifications; [Table S1](#mmc1){ref-type="supplementary-material"}) are monitored in real time. Initially, we used singly modified peptides containing either mono-methyl K4 (K4meK9) or acetyl K9 (K4K9ac). Peaks corresponding to the methyl protons of K4me, K9ac, and the free acetate product could readily be observed and distinguished in one-dimensional ^1^H NMR spectra ([Figures 2](#fig2){ref-type="fig"}A, 2B, 2F, and 2G). The HDAC and LSD1 inhibitors and inositol phosphates used in these experiments do not contain peaks that overlap with the methyl or acetyl peaks. Both demethylase and deacetylase reactions were monitored, with a range of initial H3 substrate concentrations, by using the intensities of the K4me and K9ac peaks as reporters on the concentration of the substrates in real time.Figure 2Enzymatic Coupling between LSD1 and HDAC1 in the CoREST Complex(A) The 1H NMR reference spectrum of a 330 μM sample of H3K4me, with the assignment of the K4 N(6) methyl protons shown.(B) Time series after the addition of 200 nM CoREST complex to the H3K4me substrate.(C and D) Progression curves for the conversion of ca. 300 μM (C) or 80 μM (D) H3K4me substrate incubated with 200 nM CoREST complex.(E) Filled circles are experimentally obtained substrate concentrations versus time, full-drawn lines are the results of the least-squares fits to the reaction scheme, and dashed lines represent the limiting rates after equilibrium is reached.(F) Reference 1H NMR spectrum of 670 μM H3K9ac with the assignment of the methyl protons of the K9 acetyl group shown.(G) A representative time series obtained after the addition of 50 nM CoREST complex to a 100 μM sample of H3K9ac. It is noted that both the disappearance of the H3K9ac substrate and the appearance of the acetate product can be observed, and their concentrations can be quantified from the intensity of the two peaks.(H and I) Progression curves for ca. 660 μM (H) or 100 μM (I) H3K9ac substrate concentration versus time after addition of 50 nM CoREST.

Analysis of the progression curves ([Figures 2](#fig2){ref-type="fig"}C, 2D, 2H, 2I, [S2](#mmc1){ref-type="supplementary-material"}, and [S3](#mmc1){ref-type="supplementary-material"}) for the demethylation of the K4meK9 substrate and the deacetylation of K4K9ac showed that the reactions do not follow classical Michaelis-Menten kinetics, but the apparent K~M~ and k~cat~ parameters are strongly time dependent with biphasic progression curves. This biphasic behavior is particularly pronounced for the demethylation reaction upon addition of the HDAC inhibitor MS275 and for the deacetylation reaction upon addition of the LSD1 inhibitor 2-PCPA. A number of different reactions schemes were considered, including those involving standard substrate and product inhibition ([Figure S4](#mmc1){ref-type="supplementary-material"}A; [Tables S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}). The simplest reaction scheme, which overall gave satisfactory results for both the demethylation and deacetylation reactions, is shown in [Figure 2](#fig2){ref-type="fig"}E. The key feature of this reaction scheme is that it invokes an alternate state (E^∗^) of the enzymes (HDAC1 and LSD1), which exhibit different enzymatic parameters. In particular, the first-order catalytic rate, k~cat~, and the substrate disassociation rate, *k*~−1~, are different for E and E^∗^. Moreover, the model suggests a slow unimolecular exchange between E and E^∗^ and between ES and E^∗^S. For all demethylation reactions, the catalytic rate from E^∗^S was insignificant (p ∼ 0.8; k~cat,E^∗^~ ∼ 0 s^−1^), although k~cat,E^∗^~ \> 0 s^−1^ was significant for all the deacetylation reactions (p of 0.003--0.05). The existence of an alternate state of the HDAC1 and LSD1 enzymes means that the overall reaction is highly dependent upon whether equilibrium has been reached between ES and E^∗^S. When equilibrium between ES and E^∗^S has been reached, apparent Michaelis-Menten parameters can be calculated ([Supplemental Information](#mmc1){ref-type="supplementary-material"}), which are denoted K~M,post~ and k~cat,post~ ([Tables 1](#tbl1){ref-type="table"}, [2](#tbl2){ref-type="table"}, [S4](#mmc1){ref-type="supplementary-material"}, and [S5](#mmc1){ref-type="supplementary-material"}). The dashed lines in [Figures 2](#fig2){ref-type="fig"}C, 2D, 2H, and 2I are calculated based on the limiting condition of long reaction times and ES ⇌ E^∗^S equilibrium.Table 1Summary of Kinetic Parameters Obtained for the Demethylation of K4meK9 by CoRESTAPO2-PCPA[a](#tblfn1){ref-type="table-fn"}MS275[b](#tblfn2){ref-type="table-fn"}InsP~6~[c](#tblfn3){ref-type="table-fn"}**Post-equilibrium Apparent Parameters**k~cat,post~ (s^−1^)0.032 ± 0.0020.0077 ± 0.00120.023 ± 0.0030.093 ± 0.007K~M,post~ (μM)2.3 ± 1.726 ± 59.2 ± 1.6190 ± 30k~cat,post~/K~M,post~ (s^−1^mM^−1^)14 ± 70.30 ± 0.022.5 ± 0.40.48 ± 0.04**Unimolecular Exchange***K*~eq~(E)7.0 ± 2.47.4 ± 0.51.7 ± 0.63.0 ± 0.3*k*~ex~(E) (s^−1^)0.0074 ± 0.0024\<5 × 10^−4^0.0028 ± 0.00150.0015 ± 0.0013*K*~eq~(ES)76 ± 28129 ± 30146 ± 3849 ± 4*k*~ex~(ES) (s^−1^)0.0055 ± 0.00120.0050 ± 0.00080.0060 ± 0.00240.047 ± 0.020[^8][^9][^10]Table 2Kinetic Parameters Obtained for the Deacetylation of K4K9ac by CoRESTAPO2-PCPA[a](#tblfn4){ref-type="table-fn"}InsP~6~[b](#tblfn5){ref-type="table-fn"}**Post-equilibrium Apparent Parameters**k~cat,post~ (s^−1^)0.70 ± 0.030.52 ± 0.050.78 ± 0.18K~M,post~ (μM)33 ± 622 ± 412 ± 5k~cat,post~/K~M,post~ (s^−1^mM^−1^)21 ± 223 ± 370 ± 50**Unimolecular Exchange***K*~eq~(E)6.8 ± 2.35.5 ± 2.21.9 ± 2.1*k*~ex~(E) (s^−1^)\<10^−7^0.0031 ± 0.00170.14 ± 0.17*K*~eq~(ES)2,560 ± 1,620280 ± 2201,990 ± 1,600*k*~ex~(ES) (s^−1^)0.077 ± 0.0420.0028 ± 0.00160.09 ± 0.07[^11][^12]

As might be expected, addition of the 2-PCPA LSD1 inhibitor increases the K~M,post~ of the demethylation reaction by approximately an order of magnitude and also decreases the catalytic rate by a factor of three, in agreement with the results of the fluorogenic assay in [Figure 1](#fig1){ref-type="fig"}F. Of particular interest is that the addition of the HDAC inhibitor MS275 has a profound effect on both the progression curves ([Figures 2](#fig2){ref-type="fig"}C and 2D) and kinetic parameters, obtained for the demethylation of K4meK9. The catalytic rate post-equilibrium, k~cat,post~, is only marginally affected, as is the equilibrium between ES and E^∗^S. However, K~M,post~ is about a factor of four larger and the rate E → E^∗^ is a factor of three slower. This change clearly indicates a coupling between LSD1 and HDAC1 within the CoREST complex and leads to a slower convergence toward the K~M,post~ and k~cat,post~ parameters, which is clearly visible in the experimental progression curves. These findings indicate a negative regulation, where once inhibitor or substrate is bound to HDAC1, the binding affinity for substrate to LSD1 decreases, which is also in agreement with previous observations that trichostatin A inhibited demethylation of nucleosomes ([@bib25]). Addition of InsP~6~ also has a substantial effect on the demethylase progression curves and derived kinetic parameters. Most remarkable is an increase of about two orders of magnitude in the post-equilibrium apparent Michaelis-Menten constant for K~M,post~ and an order of magnitude increase in the *k*~ex~(ES) rate such that the equilibrium between ES and E^∗^S is reached nearly within the dead time of the experiment. The obtained parameters means that, at high concentrations of substrate (\[S\]~0~ \> 200 μM), addition of InsP~6~ increases the effective rate, although for lower substrate concentrations (\[S\]~0~ \< 100 μM), addition of InsP~6~ slows the effective reaction rate.

The progression curves for the deacetylation of K4K9ac by CoREST are shown in [Figures 2](#fig2){ref-type="fig"}H and 2I for apo CoREST and for CoREST pre-incubated with the three modulators 2-PCPA, MS275, and InsP~6~. The progression curves were analyzed using the same reaction scheme as shown in [Figure 2](#fig2){ref-type="fig"}E, with the exception of the experiments in which CoREST is incubated with the HDAC inhibitor MS275, for which no reliable deacetylase parameters could be obtained. The equilibrium constants between E and E^∗^ are essentially identical for the demethylation and the deacetylation reactions under the various conditions ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). The addition of InsP~6~ results in an increase of k~cat,post~/K~M,post~ by a factor of three, which is in agreement with the results from the fluorogenic assay in [Figure 1](#fig1){ref-type="fig"}E. Most substantial is that the addition of InsP~6~ leads to a dramatic increase in the exchange rate between E and E^∗^. This effect is in line with the demethylation reaction where the addition of InsP~6~ leads to a substantial change in the exchange rates between both ES ⇌ E^∗^S and E ⇌ E^∗^.

Although both the deacetylation and the demethylation reactions are best described by the reaction scheme in [Figure 2](#fig2){ref-type="fig"}E, the alternate states, E and E^∗^, need not necessarily be the same for the two enzymes. The substantial downregulation by an HDAC inhibitor of the demethylation reaction clearly points to the fact that the two reactions/enzymes are coupled within the CoREST complex, and it seems likely that there is some form of structural coupling between the enzymes.

The coupling between the demethylation and deacetylation reactions was further substantiated by using a doubly modified substrate, K4meK9ac ([Figure S4](#mmc1){ref-type="supplementary-material"}B). In this assay, the demethylation reaction is monitored at the same time as the deacetylation reaction in real time using the NMR-based assay. The progression curves for K4meK9, K4K9ac, and K4meK9ac were analyzed simultaneously with successively more complicated reaction schemes ([Table S6](#mmc1){ref-type="supplementary-material"}). The analyses and subsequent F tests show that, with a very high confidence level, the two reactions are coupled. Specifically, (1) the CoREST complex binds only one substrate at once (p \< 10^−100^; model 2 versus model 4; [Table S6](#mmc1){ref-type="supplementary-material"}; [Supplemental Information](#mmc1){ref-type="supplementary-material"}). Thus, the HDAC1 enzyme cannot bind substrate when substrate is already bound to the LSD1 enzyme and vice versa. (2) Both the demethylation and deacetylation reactions depend on the specific substrate (p \< 10^−100^; model 3 versus model 4). That is, the kinetic parameters for deacetylation of K4meK9ac are different from those of K4K9ac and the kinetic parameters for demethylation of K4meK9ac are different from those of K4meK9---consistent with previous studies with isolated LSD1, which suggest that acetylation of K9 inhibits demethylation of K4 ([@bib12]). (3) The CoREST complex exchanges between alternate states (p \< 10^−30^; model 4 versus models 8--10). The reaction scheme with the most significant parameters, where proper convergence could be obtained, is shown in [Figure S4](#mmc1){ref-type="supplementary-material"}C.

Overall, the kinetic analyses of the two enzymes within the CoREST complex reveal that they do not act independently and that their activity and modulation by inhibitors and activators is closely coupled.

Structural Relationship between LSD1 and HDAC1 within the CoREST Complex {#sec2.3}
------------------------------------------------------------------------

Given that there appears to be coupling between the enzymatic activities of LSD1 and HDAC1 in the CoREST complex, we sought to gain an understanding of the structural relationship of the two enzymes in the complex. Attempts to obtain crystals of the ternary complex were unsuccessful, suggesting that there may be some flexibility within the complex that inhibits crystal formation. In the absence of diffraction quality crystals, as a first step, we used small angle X-ray scattering to analyze the overall shape ("envelope") of the CoREST complex. The small angle X-ray scattering (SAXS) envelope of the CoREST complex has an asymmetric bi-lobed architecture ([Figures 3](#fig3){ref-type="fig"}A and 3B). The crystal structures of HDAC1:MTA1 ([@bib29]; PDB: [4BKX](pdb:4BKX){#intref0010}) and LSD1:RCOR1 ([@bib13]; PDB: [2V1D](pdb:2V1D){#intref0015}) could be readily positioned within the SAXS envelope with the SWIRM and AOD (amine oxidase domain) domains of LSD1 in one lobe and LSD1(TOWER), RCOR1(LINKER-SANT2), and HDAC1:MTA1(SANT1) in the other lobe. We used CORAL to refine the position of the crystal structures and to model terminal regions of the proteins as well as the RCOR1 linker so as to optimize the fit with the SAXS data ([@bib32]). The theoretical scattering curve calculated from this refined model of holo CoREST complex gave a reasonable agreement with the experimental data ([Figure 3](#fig3){ref-type="fig"}C). However, a Kratky plot of the SAXS data suggests that the complex may have conformational flexibility, limiting the quality of the fit ([Figure 3](#fig3){ref-type="fig"}D).Figure 3The CoREST Ternary Complex has a "Bi-lobe" Structure(A) View of the SAXS envelope of the CoREST ternary complex fitted using CORAL with the crystal structures of the MTA1:HDAC1 (PDB: [4BKX](pdb:4BKX){#intref0140}; [@bib29]) and LSD1:RCOR1 (PDB: [2V1D](pdb:2V1D){#intref0145}; [@bib13]) complexes. The linker and terminal disordered regions are modeled and indicated by small C-alpha spheres.(B) View as in (A) but rotated by 90°.(C) SAXS data for the CoREST ternary complex with the experimental scattering curve (blue) and theoretical scattering curve (red) from the LSD1:RCOR1:HDAC1 model. The residual errors of the fit are shown below the curve.(D) A Kratky plot indicating that the CoREST complex is conformationally flexible.(E) The CoREST ternary complex was cross-linked with increasing concentrations of CBDPSS.(F) Schematic showing the CBDPSS cross-links identified in the CoREST ternary complex using mass spectrometry. Dotted lines indicated the cross-linked residues with the xQuest ID score above 14.5.(G) The SAXS-derived model of the CoREST ternary complex with cross-linked residues highlighted with dotted lines in pink. Black arrows indicate the active sites of HDAC1 and LSD1.

To test this model of the CoREST complex, we used cross-linking analysis together with mass spectrometry to identify interacting surfaces. The purified CoREST complex was cross-linked by an isotopically coded NHS-activated ester cross-linking reagent ([Figure 3](#fig3){ref-type="fig"}E). Liquid chromatography-mass spectrometry (LC-MS) analysis identified cross-linked residues ([Figure 3](#fig3){ref-type="fig"}F). Rather few cross-links that report on the relationship between HDAC1 and LSD1 were identified. However, a cross-link between lysine 220 in HDAC1 with lysine 447 in the LSD1 TOWER domain was particularly informative. This cross-link is clearly compatible with the SAXS-derived model of the CoREST ternary complex ([Figure 3](#fig3){ref-type="fig"}G).

Negative-stain electron microscopy was used to further investigate the architecture of the holo CoREST complex. Samples of a lightly cross-linked CoREST complex were applied to a carbon-coated copper grid and stained with uranyl acetate (see [STAR Methods](#sec4){ref-type="sec"} for details of sample preparation). The resulting transmission electron microscopy (TEM) images revealed a homogeneous sample that enabled straightforward manual particle picking in the EMAN2 software ([Figure 4](#fig4){ref-type="fig"}A). Two-dimensional class averages generated using Relion revealed a clear two-lobed complex joined by a linker ([Figure 4](#fig4){ref-type="fig"}B). This bi-lobed shape fits well with the SAXS envelope. A 3D envelope for the structure was generated using CryoSparc at an approximate resolution of 18 Å ([Figures 4](#fig4){ref-type="fig"}C and 4D). The coordinates for the known structure of the LSD1:RCOR1 complex and a model of the HDAC1:RCOR1 complex (based on the HDAC1:MTA1 structure) could readily be fitted into this envelope. In the resulting model, the HDAC1 is located at the far end of the TOWER domain adjacent to the SANT2 domain of RCOR1. In addition to the clearly defined bridge between the two lobes, formed from the TOWER domain of LSD1 and the LINKER domain of RCOR1, there is evidence of a second less substantial linker. This second linker can be rationalized given that there must be a connection between the C terminus of the RCOR-SANT1 domain and the N terminus of the coiled coil LINKER domain of RCOR1 ([Figure 4](#fig4){ref-type="fig"}E). However, due to the limited resolution, it is difficult to confidently orient HDAC1 and its bound SANT1 domain within the lower lobe of the structure. It is also likely that the SANT2 domain from RCOR1 may be repositioned somewhat, compared with the crystal structure, to accommodate the HDAC1/RCOR1-SANT complex.Figure 4Structural Models of the CoREST Complex Generated Using Negative Stain and Cryo-electron Microscopy(A) Electron micrograph of negatively stained CoREST complex.(B) Reference-free 2D class averages of the particles used to generate the 3D model.(C) Fourier shell correlation plot (CryoSparc). The resolution of the EM model was approximately 18 Å.(D) Different views of the EM model of the CoREST complex (gray) fitted with the crystal structures of the MTA1:HDAC1 and LSD1:RCOR1 complexes. LSD1 is shown in cyan, HDAC1 in salmon, and MTA1/RCOR1 in green.(E) Schematic representation of the structural arrangement of the CoREST complex. RCOR1 is green. The ELM2, SANT1, and SANT2 domains are indicated E2, S1, and S2, respectively.(F) Refined 3D model of the glutaraldehyde cross-linked CoREST complex. The estimated resolution is 17.5 Å (Relion).(G) Two different structural models were generated for the BS^3^ cross-linked CoREST complex: a closed form (20 Å), which closely matches the glutaraldehyde cross-linked complex, and an open form (21.5 Å), in which the HDAC1 is pivoted away from the LSD1 tower domain.

Given the homogeneity of the complex on negative-stain electron microscopy (EM) grids, we were hopeful to determine a higher resolution structure using samples flash frozen in vitrified ice (cryoelectron microscopy \[cryo-EM\]). A variety of different EM grids were prepared using a range of different buffer and cross-linking conditions. Cryo-EM data of the CoREST complex, lightly cross-linked with glutaraldehyde, revealed once again a clear bi-lobed structure in the 2D class averages ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Calculation of a 3D model did not yield a structure with significantly increased resolution but revealed a clearly asymmetric bi-lobed envelope ([Figure 4](#fig4){ref-type="fig"}F). This allowed unambiguous fitting of the LSD1:RCOR1 crystal structure. The remaining density could accommodate the HDAC1:SANT in a similar position to the model fitted in the envelope obtained from the negative stain data.

We also collected cryo-EM data for the CoREST complex cross-linked with BS^3^ using a Volta phase plate. The 2D class averages from these micrographs were rather less homogeneous ([Figure S5](#mmc1){ref-type="supplementary-material"}D). Calculation of 3D models revealed two distinct conformations for the CoREST complex ([Figure 4](#fig4){ref-type="fig"}G). The first closely resembles the structure seen in both the negatively stained dataset and the glutaraldehyde cross-linked dataset in ice. In the second conformation, the HDAC1 is pivoted away from the coiled coil of the LSD1 TOWER. We refer to these as "closed" and "open" conformations. Interestingly, in the BS^3^ cross-linked complex, in both frozen and negatively stained complex, we observed some class averages in which the HDAC1 was apparently fully detached from the LSD1 TOWER and relocated toward the LSD1(AOD) domain ([Figure S5](#mmc1){ref-type="supplementary-material"}E). We believe that this is likely to be an artifact arising from partial disassembly of the complex as a result of the harsh grid preparation process. Furthermore, in the absence of cross-linking, it was only possible to observe isolated LSD1 on cryo-EM grids ([Figure S5](#mmc1){ref-type="supplementary-material"}E), emphasizing that the freezing process is damaging to the integrity of the complex.

Structure of the CoREST Complex Bound to a Mono-nucleosome {#sec2.4}
----------------------------------------------------------

Although we have been unable to determine a high-resolution structure of the CoREST complex, we sought to gain insights into the interaction of the holo-complex with a mono-nucleosome substrate. We took the strategy of preparing site-specific modified nucleosomes that contain a propargylamine mimic of histone H3 K4me2 ([@bib8], [@bib13]). The nucleosome was assembled with 185-bp 601 DNA ([@bib27]), because it has been suggested that linker DNA is required for tight binding between CoREST and nucleosomes ([@bib22], [@bib49]). This 185-bp H3K4-propargyl nucleosome was designed to stabilize binding of the nucleosome to the FAD (flavin adenine dinucleotide) at the LSD1 active site ([@bib8]).

The complex between the 185-bp H3K4-propargyl nucleosomes and the holo CoREST complex was prepared at various sample ratios ([Figure 5](#fig5){ref-type="fig"}A). The holo CoREST complex forms both 1:1 and 2:1 bound complexes with the 185-bp H3K4-propargyl nucleosomes. However, a percentage of unbound nucleosome was always observed, even on adding excess CoREST. In order to reduce the heterogeneity of the sample, we performed a further purification step through a 2.4 mL Superdex 200 column (3.2/300). The fraction containing the largest proportion of CoREST:nucleosome 1:1 complex was selected and cross-linked with glutaraldehyde to make a sample for negative stain EM ([Figure S7](#mmc1){ref-type="supplementary-material"}). Attempts to purify a CoREST:nucleosome 2:1 complex were not successful due to too much heterogeneity.Figure 5Structural Model of the CoREST Complex Bound to Semi-synthetic H3K4-Propargyl-Modified Nucleosome (Negative-Stain EM)(A) Electrophoretic mobility shift assay (EMSA) assay of the CoREST complex (labeled LHC) binding to 185-bp H3K4-propargyl nucleosome.(B) Reference-free 2D class averages of the particles used to generate the 3D model.(C) Fourier shell correlation plot (Relion3.0). The resolution of the EM model was approximately 26 Å.(D) 3D envelope of the CoREST complex bound to the nucleosome.(E) Crystal structures of the nucleosome, HDAC1, LSD1, and RCOR1 fitted into the EM envelope. H3, blue; H4, dark green; H2A, yellow; H2B, red (PDB: [1AOI](pdb:1AOI){#intref0150}; [@bib28]).(F and G) Orthogonal views of the charged surface of the LSD1:RCOR positioned as seen in the EM structure of the CoREST complex bound to a nucleosome. The binding surface for RNA (nucleic acid) is highlighted as is the LSD1 active site with the H3 peptide (1--16 aas) shown in purple (PDB: [2V1D](pdb:2V1D){#intref0155}, [@bib13]; PDB: [4XBF](pdb:4XBF){#intref0160}, [@bib17]).

The micrographs of the predominantly 1:1 complex gave rise to rather heterogeneous 2D class averages. However, the majority of particles fell into a limited number of highly populated classes ([Figure 5](#fig5){ref-type="fig"}B). These clearly contain the familiar bi-lobed particles of the CoREST complex bound to a larger particle that resembles the known structure of a nucleosome. Using these highly populated class averages, it was possible to generate a 3D structural model of the complex with a nominal resolution of 26 Å ([Figures 5](#fig5){ref-type="fig"}C and 5D). The bi-lobed density of the CoREST complex strongly resembled the previous compact models observed in both the negative stain and cryo-EM grids. We were readily able to dock the known structures into the envelope ([Figure 5](#fig5){ref-type="fig"}E). It is clear that LSD1 within the CoREST complex is bound to the nucleosome ([@bib28]; PDB: [1AOI](pdb:1AOI){#intref0020}) in such a way that the H3K4-propargyl group is able to engage with the active site of the LSD1 demethylase. When LSD1 is engaged with the substrate, the HDAC1 is rather far from the nucleosome and may not be able to target histone tails in the same nucleosome. Interestingly, positively charged residues in LSD1 are positioned such that they can mediate interaction with the phosphate backbone of the DNA around the dyad. Furthermore, the positively charged region that has been previously found to interact with RNA is ideally positioned to interact with the emerging linker DNA ([@bib17]; [Figures 5](#fig5){ref-type="fig"}F and 5G).

Discussion {#sec3}
==========

We have expressed and purified a stable ternary CoREST complex in mammalian HEK293F cells. The complex is monomeric, and both enzymes in the complex are active, demonstrating that the complex is fully functional. In previous studies, we have used this complex to characterize a combined deacetylase and demethylase inhibitor and to investigate specificity of the complex for different modifications on a reconstituted nucleosome substrate ([@bib21], [@bib49]). In these studies, we noticed that the demethylase activity did not appear to follow Michaelis-Menten kinetics and therefore established a simultaneous, real-time demethylase and deacetylase assay. Using this approach, we have shown that the two enzymes within the CoREST complex, HDAC1 and LSD1, are coupled and mutually influence the activity of the other enzyme. Consistent with this, we showed that inhibitors and activators of one enzyme also influence the activity of the other enzyme. Indeed, the effects of InsP~6~ are greater on the demethylase than the deacetylase reaction. Furthermore, we have found that both enzymes exist in at least two distinguishable states that differ in their kinetic properties. It is likely that this reflects two structurally distinct states of the complex. We also observed that the complex can only engage with one substrate at a time. However, a limitation of this study is that isolated peptides were used for the ^1^H NMR-based assays rather than nucleosomes, because nucleosomes will impose spatial restraints that could influence the accessibility of the H3 tails.

To date, there have been no structural studies of the CoREST ternary complex. However, there have been numerous crystallographic studies of the LSD1:RCOR1 complex as well as modeling to predict the mode of interaction with nucleosomes ([@bib7], [@bib5], [@bib6], [@bib13], [@bib35], [@bib52], [@bib51]). Although there is no structure of HDAC1 in complex with RCOR1, the structure of HDAC1:MTA1 complex ([@bib29], [@bib48]) enables us to model the HDAC1:RCOR1 complex.

To investigate the physical relationship between the HDAC1 and LSD1 in the ternary complex, we have used SAXS, cross-linking-MS, negative-stain EM, and cryo-EM. The results from these complementary approaches are consistent with each other and reveal a bi-lobed structure with the LSD1 demethylase at one end and the HDAC1 at the other. The known LSD1:RCOR1 and HDAC1 structures fit well within the SAXS and EM envelopes. The orientation of the LSD1 is relatively well defined by the distinctive tower domain. In contrast, the orientation of the HDAC1 is less well defined and the calculated best fit to each of the EM envelopes is somewhat variable. In all the structures, HDAC1 is positioned close to the SANT2 domain of RCOR1 and likely makes a direct interaction with this domain. Previous models of the LSD1:RCOR1 in complex with a nucleosome have suggested that the SANT2 domain might bind to the outer surface of the DNA wrapped around the nucleosome ([@bib35], [@bib51]). This has led to the concept of a nanoscale clamp positioning the LSD1:RCOR1 around the nucleosome ([@bib5], [@bib6]). The position of HDAC1 we observe in the ternary complex shows that it is in close proximity to the SANT2 domain. This suggests that it is unlikely that the ternary complex would be able to interact with a nucleosome in the way that has been predicted.

It is interesting that, in the BS^3^ cross-linked cryo-EM sample, we observe a second (less populated) form of the complex. In this complex, the HDAC1 appears to be rotated away from the LSD1 TOWER domain. Although it is not possible to rule out that this is an artifact of the grid preparation and flash freezing, it may reflect an alternative form of the complex. It certainly seems likely that the alternative state of the complex revealed from the enzyme kinetics results from some structural change in the complex. Interestingly, molecular dynamics analyses of the LSD1:RCOR1 complex have suggested that the SANT2 domain may rotate and swing with respect to the TOWER of LSD1 ([@bib5], [@bib6]). This is consistent with the motion that would be required to create the alternative conformation under the BS^3^ cross-linking conditions.

Given that that the structure we observe for the ternary CoREST complex appears inconsistent with previous models of how LSD1:RCOR1 binds nucleosomes, we wished to investigate how the ternary CoREST complex interacts with a mono-nucleosome using negative-stain EM. To aid formation of a stable complex, we prepared a modified nucleosome in which H3K4 was replaced with a propargylamine group that can form a non-reversible coupling with the FAD co-factor in the active site of LSD1. We reasoned that the resulting complex would provide an experimental understanding of how LSD1, in the context of the ternary CoREST complex, targets methylated K4 in a chromatin substrate.

Although the 2D class averages revealed some heterogeneity in the complex, a dominant proportion of particles were grouped into a small consistent set of class averages, in which the bi-lobed CoREST complex was clearly docked with the edge of the nucleosome disk. The HDAC1 is rather distant from the nucleosome and unlikely to be able to interact with histone tails from the same nucleosome. It may be possible for HDAC1 to target an adjacent nucleosome; however, the enzymology suggests that only one substrate can be engaged at a time. The LSD1 is positioned such that a relatively basic surface of the demethylase domain of LSD1 (but not the SWIRM domain) interacts with the nucleosomal DNA close to the dyad of the nucleosome, where the linker DNA enters and leaves the nucleosome. The H3K4-propargyl in the histone tail can readily reach the active site of LSD1. Intriguingly, the region of LSD1 that has previously been shown to interact with RNA ([@bib17]) is positioned very close to where the linker DNA would likely interact with the LSD1 demethylase domain. It is not clear what the implications of this might be. However, two studies have shown that CoREST preferentially binds nucleosomes with longer linker DNA ([@bib22], [@bib49]). This finding prompted us to use 185-bp DNA in this structure. Unfortunately, the linker DNA is not visible at this resolution, and a more detailed understanding of this will require a higher resolution structure.

In conclusion, our investigation into the CoREST ternary complex has revealed a molecular machine in which the two enzymes, deacetylase and demethylase, are functionally and structurally coupled.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Chemicals, Peptides, and Recombinant Proteins**Polyethylenimine (PEI)Sigma-AldrichCAT\# 408727Anti-Flag M2 affinity gelSigma-AldrichCAT\# A2220Rink Amide SpheriTide resin (1.05 mmol/g substitution)CEMCAT\# R002-AFmoc-Ala-OHNovabiochemCAT\# 852003 CAS\# 35661-39-3Fmoc-Arg(Pbf)-OHNovabiochemCAT\# 852067 CAS\# 154445-77-9Fmoc-Thr(^t^Bu)-OHNovabiochemCAT\# 852000 CAS\# 71989-35-0Fmoc-Lys(Me,Boc)-OHNovabiochemCAT\# 852106 CAS\# 951695-85-5Fmoc-Gln(Trt)-OHNovabiochemCAT\# 852045 CAS\# 132327-80-1Fmoc-Lys(Boc)-OHNovabiochemCAT\# 852012 CAS\# 71989-26-9Fmoc-Ser(tBu)OHNovabiochemCAT\# 852019 CAS\# 71989-33-8Fmoc-Gly-OHNovabiochemCAT\# 852001 CAS\# 29022-11-5Fmoc-Pro-OHNovabiochemCAT\# 852017 CAS\# 71989-31-6Fmoc-Leu-OHNovabiochemCAT\# 852011 CAS\# 35661-60-0Fmoc-Lys(Ac)-OHNovabiochemCAT\# 852042 CAS\# 159766-56-0*N*,*N*-dimethylformaldehyde (DMF)Rathburn ChemicalsCAT\# PTS6020 CAS\# 68-12-21-Methyl 2-pyrrolidone (NMP)Rathburn ChemicalsCAT\# PTS6035 CAS\# 872-50-4PiperidineSigma-AldrichCAT\# 104094 CAS\# 110-89-4O-(1H-6-Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU)NovabiochemCAT\# 851012 CAS\# 330645-87-9OxymaPureNovabiochemCAT\# 8.51086 CAS\# 3849-21-6Diisopropylethylamine (DIPEA)Sigma-AldrichCAT\# D125806 CAS\# 7087-68-5Trifluoroacetic acid (TFA)Sigma-AldrichCAT\# T6508 CAS\# 76-05-1Triethylsilane (TES)Sigma-AldrichCAT\# 230197 CAS\# 617-86-7Fmoc-Gln(Trt)-Thr(ψMe,Mepro)-OHNovabiochemCAT\# 8.52198 CAS\# 1572725-72-4Fmoc-Ser(tBu)-Thr(ψMe,Mepro)-OHNovabiochemCAT\# 8.52192CAS\# 1266350-99-5MS-275 (Entinostat, SNDX-275)Sigma-AldrichCAT\# EPS002 CAS\# 209783-80-2TSA (Trichostatin A)Sigma-AldrichCAT\# T8552 CAS\# 58880-19-6SAHA (Vorinostat)Sigma-AldrichCAT\# SML0061 CAS\# 149647-78-92-PCPA (*trans*-2-Phenylcyclopropylamine hydrochloride)Sigma-AldrichCAT\# P8511 CAS\# 1986-47-6InsP~4~ (D-myo-Inositol-1,4,5,6-tetraphosphate)Cayman ChemicalCAT\# 10007783 CAS\# 157542-47-7InsP~5~ (D-myo-Inositol-1,3,4,5,6-pentaphosphate)Cayman ChemicalCAT\# 10007784InsP~6~ (Phytic Acid)Sigma-AldrichCAT\# 68388 CAS\# 14306-25-3Boc-Lys(ac)-AMCBaChemCAT\# 4033972Horseradish peroxidase (HRP), EIA gradeThermoFisher ScientificCAT\# 012001Amplex Red ReagentThermoFisher ScientificCAT\# A22177CBDPSSCreative Molecules Inc.CAT\# 014SSGlutaraldehydeSigma-AldrichCAT\# G5882 CAS\# 111-20-8BS^3^ (Sulfo-DSS) CrosslinkerThermoFisher ScientificCAT\# A392662-(Methylamino)ethanolSigma-AldrichCAT\# 471445 CAS\# 109-83-1Propargyl bromideSigma-AldrichCAT\# 81831 CAS\# 106-96-7Histone proteins([@bib49])N/AH3K4me 1-21 peptideThis paperN/AH3K9ac 1-21 peptideThis paperN/AH3K4meK9ac 1-21 peptideThis paperN/A**Deposited Data**Negative stain map: CoREST complexEMDBEMDB: EMD-10626Cryo-EM map: Glutaraldehyde crosslinked complexEMDBEMDB: EMD-10627Cryo-EM map: BS3 crosslinked complex-closed formEMDBEMDB: EMD-10628Cryo-EM map: BS3 crosslinked complex-open formEMDBEMDB: EMD-10629Negative stain map: CoREST-nucleosome complexEMDBEMDB: EMD-10630SAXS dataSASDBSASDB: SASDH45**Experimental Models: Cell Lines**FreeStyle 293-F cellsThermoFisher ScientificCAT\# R79007**Oligonucleotides**5′ Primer for cloning CoREST (aa 86) protein into pLEICS12 vector: GTATTTTCAGGGCGCCATGTG\
GGAGGAAGGCAGCEurofins GenomicsN/A3′ Primer for cloning CoREST protein (aa 485) into pLEICS12 vector: GACGGAGCTCGAATTTCAGG\
AGGCAGATGCATATCTEurofins GenomicsN/A5′ Primer for cloning LSD1 protein (aa 1) into pLEICS12 vector: ACCCAAGCTTGGTACCATGTT\
ATCTGGGAAGAAGGCGEurofins GenomicsN/A3′ Primer for cloning LSD1 protein (aa 852) into pLEICS12 vector: GACGGAGCTCGAATTTCACA\
TGCTTGGGGACTGCTGTGCEurofins GenomicsN/A5′ Primer for the mutagenesis of H3(K4C):\
CTCGTACTTGTCAGACCGCCCGCAAGIDTN/A3′ Primer for the mutagenesis of H3(K4C):\
GGCGGTCTGACAAGTACGAGCCATATGIDTN/A185 bp 601 DNA([@bib49])N/A**Recombinant DNA**IMAGE clone: CoRESTSource BioScienceID: 40080558IMAGE clone: LSD1Source BioScienceID: 5298150Plasmid: pLEICS12-(His)~10~(Flag)~3~-CoREST(aa 86-485)This paperN/APlasmid: pLEICS12-LSD1 (full length)This paperN/APlasmid: pLEICS12-HDAC1 (full length)([@bib29])N/A**Software and Algorithms**Prism (version 7.0)GraphPad<https://www.graphpad.com/scientific-software/prism/>NMRPipe([@bib9])<https://www.ibbr.umd.edu/nmrpipe/install.html>FuDA([@bib15])<https://www.ucl.ac.uk/hansen-lab/>NMR data fitting algorithmsThis paper<https://www.ucl.ac.uk/hansen-lab/>ScÅtter([@bib19])<http://www.bioisis.net>; <https://bl1231.als.lbl.gov/scatter>SAXS MoW([@bib34])<http://saxs.ifsc.usp.br/>CORAL([@bib32])<https://www.embl-hamburg.de/biosaxs/atsas-online/coral.php>CRYSOL([@bib43])<https://www.embl-hamburg.de/biosaxs/atsas-online/crysol.php>xQuest([@bib26])<http://prottools.ethz.ch/orinner/public/htdocs/xquest/>EMAN2([@bib44])<https://blake.bcm.edu/emanwiki/EMAN2>SPHIRE-crYOLO([@bib45])<http://sphire.mpg.de/wiki/doku.php?id=pipeline:window:cryolo>Relion2([@bib40])<https://www3.mrc-lmb.cam.ac.uk/relion/index.php/Main_Page>Relion3.0([@bib57])CryoSparc([@bib37])<https://cryosparc.com/>Pymol (Version 1.8)Schrödinger, LLC<https://pymol.org/2/>Chimera (Version 1.13.1)([@bib33])<https://www.cgl.ucsf.edu/chimera/>

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, John Schwabe (<john.schwabe@le.ac.uk>).

All unique reagents generated in this study are available from the lead contact with a completed Materials Transfer Agreement.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mammalian Protein Expression {#sec4.3.1}

The CoREST ternary complex was comprised of full length LSD1 (UniProt ID: [O60341](uniprotkb:O60341){#intref0100}), full length HDAC1 (UniProt ID: [Q13547](uniprotkb:Q13547){#intref0105}) and N-terminally truncated RCOR1 (86-485aa) (UniProt ID: [Q9UKL0](uniprotkb:Q9UKL0){#intref0110}). The pcDNA3 vector was used to create plasmids encoding the different proteins. The RCOR1 constructs contained an N-terminal (His)10(Flag)3 tag followed by a Tev protease cleavage site. The constructs for ternary complex were co-transfected into suspension-grow HEK293F cells (ThermoFisher Scientific) with polyethylenimine (PEI) (Sigma) and harvested after 48 hours as described previously ([@bib21], [@bib49]).

Method Details {#sec4.4}
--------------

### Mammalian Protein Purification {#sec4.4.1}

Cells were lysed in buffer containing 50 mM Tris/Cl pH 7.5, 50 mM potassium acetate, 5% v/v glycerol, 0.4% v/v Triton X-100, and Roche Complete Protease Inhibitor (buffer A). Insoluble materials were removed by centrifugation. The complex was purified on Flag resin (Anti-Flag M2 affinity gel, Sigma). The resin was washed once with buffer A, three times with buffer B (50 mM Tris/Cl pH 7.5, 50 mM potassium acetate, and 5% v/v glycerol), and three times with buffer C (50 mM Tris pH 7.5, 50 mM potassium acetate, 5% v/v glycerol and 0.5 mM TCEP) followed by an overnight TEV protease cleavage in buffer C. The complex was further purified by gel filtration chromatography on a Superose 6 column (GE Healthcare) in buffer containing 25 mM Tris pH 7.5, 50 mM potassium acetate, and 0.5 mM TCEP.

### Size-Exclusion Chromatography with Multi-Angle Light Scattering (SEC-MALS) {#sec4.4.2}

Purified CoREST ternary complex that has been gel filtrated was concentrated to \> 1 mg/ml. The complex was reapplied to a Superose 6 column. The mass of the complex was detected on elution with an 18-angle MALS light scattering detector (Dawn® HELEOS® II) coupled with a differential Refractive Index detector (Optilab® T-rEX) (Wyatt Technology).

### Boc-Lys(Ac)-AMC HDAC Assay {#sec4.4.3}

HDAC activity of the CoREST complex was measured using a fluorescent-based HDAC assay with Boc-Lys(Ac)-AMC substrate. 25 nM of purified complex, and 500 μM of substrate were used in a final volume of 50 μl in assay buffer (50 mM Tris pH 7.5, 50 mM NaCl, 0.1 mg/ml BSA). Inositol phosphates (100 μM) and HDAC inhibitors (5 μM) were tested for their ability to activate or repress the complex by pre-incubating with the complex in varying concentrations at 37°C for 30 minutes before adding the substrate. The assay was developed by the addition of 50 μl of developer solution (2 mM TSA, 10 mg/ml Trypsin, 50 mM Tris pH 7.5, 100 mM NaCl). Fluorescence was measured at 335/460 nm using a Victor X5 plate reader (Perkin Elmer). Data analyzed using GraphPad Prism (version 7.0, GraphPad Software, Inc.).

### Horse Radish Peroxide (HRP)-coupled Demethylase Assay {#sec4.4.4}

The Demethylase assay was performed using an Amplex UltraRed reagent (Thermo Fisher Scientific) which fluoresces on a per-mole basis in a HRP-coupled assay ([@bib56]). A final concentration of 50 nM CoREST complex was used in a reaction volume of 100 μl. For LSD1 inhibition by LSD1 inhibitors, the protein sample was pre-incubated with the inhibitors for half hour in assay buffer containing 20 mM HEPES pH 7.5 and 50 mM NaCl at room temperature. Amplex UltraRed reagent (10 μM) and HRP (0.04 mg/ml) were added before the assay was initiated with 15 μM of H3K4me peptide substrate. Fluorescence was measured at 530/590 nm using a Victor X5 plate reader (Perkin Elmer) after 30 minutes. All measurements were performed in triplicate and data analyzed using GraphPad Prism.

### Peptide synthesis for NMR based enzymatic assay {#sec4.4.5}

The peptides were synthesized on a Biotage Initiator^+^ Alstra machine on Rink Amide SpheriTide resin (1.05 mmol/g substitution, CEM). Fmoc-protected amino acids were made up as a solution of 0.2 M in DMF to give 5 equivalents relative to the resin once added to the reaction vessel. The activator was made up to 0.5 M HCTU in DMF and the activator base was made up to 2 M DIPEA in NMP. These solutions allowed for 5 equivalents of activator and 10 equivalents of activator base relative to the resin. Deprotection solution was made up to 20% v/v piperidine in DMF solution with 0.1M OxymaPure. Double coupling of Fmoc-Arg(Pbf)-OH was carried out at room temperature for 25 mins, then heated to 75°C for 5 mins, drained and a second coupling step carried out at 75°C for 5 mins. All other amino acids were coupled at 75°C for 5 mins. Deprotections were carried out at 75°C for 30 s, followed by a second deprotection at 75°C for 3 mins. Pseudoproline residues were used to help prevent the formation of on-resin secondary structures. Fmoc-Gln(Trt)-Thr(ψMe,Mepro)-OH for Gln5-Thr6 and Fmoc-Ser(tBu)-Thr(ψMe,Mepro)-OH for Ser11-Thr12.

Synthesized peptides were cleaved from the resin using a cleavage cocktail of TFA/TES/water (95:2.5:2.5) for 3 hours before being drained and the TFA blown off with a stream of nitrogen. The peptide was precipitated and washed three times in cold diethyl ether and spun down to a pellet before the diethyl ether removed and the peptide dried under a steady stream of nitrogen.

Crude peptides were purified by reverse-phase HPLC using a Dionex Ultimate 3000 system with a Phenomenex Gemini-NX 5 μm C18 110 Å AXIA packed column with dimensions 250 × 21.20 mm and purity confirmed by analytical reverse-phase HPLC using a Dionex Ultimate 3000 system with a Phenomenex Aeris 5 μm Peptide XB-C18 100 Å packed column with dimensions of 150 × 4.6 mm. LC-MS were run using a Xevo QTof mass spectrometer (Waters) coupled to an Acquity LC system (Waters) using an Acquity UPLC BEH C18 column (2.1 × 50 mm, Waters). The flow rate was 0.6 mL min^-1^ and the gradient was as follows: 95% Solvent A (0.1% formic acid in water) with 5% solvent B (0.1% formic acid in acetonitrile) was held constant for 0.5 min, followed by a linear gradient to 100% B over the next 2.1 min. After 1 min at 100% solvent B, the gradient was returned to 95% solvent A and 5% solvent B over 0.2 min. The ESI capillary voltage was 3 kV, cone voltage 30 V and collision energy 4 eV. The MS acquisition rate was 10 spectra per second and m/z data ranging from 50 to 2000 Da was collected. Mass accuracy was achieved using a reference lock mass scan, once every 10 s. Water was removed by lyophilisation using a FreeZone Benchtop Freeze Dry System. The purity of the peptides used in the biological assays were determined to be greater than 95% in all instances.

### 1D-NMR based Real-time Enzymatic Assay {#sec4.4.6}

#### NMR sample preparation {#sec4.4.6.1}

The CoREST ternary complex was purified and used in this assay. The protein was gel filtrated in buffer containing 10 mM Tris pH 7.5, 50 mM KCl and 0.5 mM TCEP. Substrate peptides were dissolved in the same buffer as the gel filtration buffer.

#### NMR experiments {#sec4.4.6.2}

Substrate peptide samples were prepared to yield a final concentration in a range from 50 μM to 800 μM (final volume of 600 μl, in a 5 mm Wilmad®NMR tube) with 5% D~2~O. A reference ^1^H 1D spectrum was recorded using excitation sculpting water suppression, 4 dummy scans, 16 scans, a recovery delay of 1 s and an acquisition time of 2.04 s, leading to a total acquisition time of 61 s. 16k complex points were recorded with a sweep width of 8012 Hz. Protein was added to start the enzymatic reaction with a final concentration of 50 -- 200 nM in a final volume of 600 μl. Inhibitors were pre-incubated with the complex for 30 minutes. One round of gradient shimming was performed followed by the acquisition of a series of 1D ^1^H NMR spectra with the same parameters as the reference spectrum. The time between the addition of the CoREST complex and the acquisition of the first 1D 1H NMR experiment was started was approximately 80 s and this 'deadtime' was noted for each time series. 1D-NMR spectra were recorded on a Bruker Avance 500 over a certain time course.

### Analysis of NMR spectra {#sec4.4.7}

The NMR spectra were processed using NMRPipe ([@bib9]), using a 1.8 Hz exponential line broadening prior to Fourier transformation. A polynomial baseline correction as implemented in NMRPipe was applied after the Fourier transform. All 1D ^1^H NMR spectra within a time series were collected into a pseudo 2D spectrum. Signal intensities were determined using the program FuDA as described previously ([@bib15]) by fitting a mixed Gaussian/ Lorentzian line shape to each peak and assuming a common line shape for a given peak during a time series (i.e., line shape and peak positions are independent of time). Subsequently the peak intensities were converted to concentrations (in μM) by using a reference sample with known concentration.

### Data analysis of NMR based enzymatic assay {#sec4.4.8}

Least-squares fitting of kinetic parameters: A program was written in C++ to analyze the obtained substrate concentrations versus time and to extract kinetic parameters and standard errors. In the program the ordinary differential equations that describe the kinetics were integrated numerically over the time domain using a controlled adaptive Runge-Kutta Cash-Karp ([@bib3], [@bib1]) stepper in the odeint function implemented in the C++ boost class library (<https://www.boost.org>). Thus, for each set of rate constants, {k~j~}~j~, and initial substrate concentrations \[S\]~0,i~, the progression curves originating for different initial substrate concentration but same rates constants, \[S\]~calc~(t; S~0,i~, k~j~) were calculated.

Best-fit parameters were obtained using a Levenberg-Marquardt least-squares fitting algorithm similar to that described by [@bib36]. The model fitting parameters included the initial concentrations of the substrate and the micro-kinetic rate constants, expect for the second-order substrate-enzyme association rate, k~1~. Specifically, the χ^2^ that was minimized in the fit was defined as$$\text{χ}^{2}\left( {\text{t};\text{S}_{0,\text{i}},\text{k}_{\text{j}}} \right) = \sum\limits_{\text{i},\text{k}}\frac{\left( {\left\lbrack \text{S} \right\rbrack_{\text{calc}}\left( {\text{t}_{\text{k}};\text{S}_{0,\text{i}},\text{k}_{\text{j}}} \right) - \left\lbrack \text{S} \right\rbrack_{\text{i},\text{exp}}\left( \text{t}_{\text{k}} \right)} \right)^{2}}{\text{σ}^{2}}$$where the sum over i is the experiments with different initial substrate concentration and the sum over k is the different time points, where the substrate concentration was observed experimentally. The uncertainty σ was set to 1 μM for all points as judged from the signal-to-noise. The derivatives d\[S\]~calc~/dS~0,i~ and d\[S\]~calc~/dk~j~ used to generate the Jacobi matrix for the least-squares fit were obtained numerically and only elements of the Jacobi matrix that were know *a priori* to be non-zero were calculated.

Extensive grid searches were performed initially to obtain good starting parameters for the fit. Standard errors of the obtained model parameters were determined from the co-variance matrix ([@bib36]) or by a bootstrap approach (500 runs) ([@bib11]). Each least-squares fit of the singly modified substrates K4MeK9 and K4K9Ac took approximately 15 min on a desktop computer with sixteen 3.2 GHz processors. Significance p-levels were calculated using F-tests and the incomplete beta-function. The program and source codes are available from the authors upon request.

Considerations made in regards to the least-squared analysis: It was assumed that the second order association rate constant between E and S and between E^∗^ and S are identical and equals k~1~. Initial analyses, grid searches, and chi-square analyses showed that the data does not contain sufficient information for an accurate value of k~1~ to be determined, yet k~1~ is close to the diffusion limit. In all the analyses it was therefore assumed that k~1~ = 200,000 s^-1^M^-1^. Larger values for k~1~ increased the time for solving the coupled differential equations, however it did not improve the chi-square, while smaller values slightly increased the obtained chi-square, χ^2^.

The reaction scheme in [Figure 3](#fig3){ref-type="fig"} is circular between the four species E, ES, E^∗^S and E^∗^. Therefore, although there are eight rate constants between E, E^∗^, ES and E^∗^S, there are only seven independent rates if the system is to be thermodynamically stable. In the analysis, the value for the disassociation of E^∗^S was chosen to be calculated from the other rate constants:$$\text{k}_{- 1 \ast} = \frac{\text{k}_{- \text{ES}}}{\text{k}_{\text{ES}}}\frac{\text{k}_{\text{E}}}{\text{k}_{- \text{E}}}\text{k}_{- 1} = \frac{\text{K}_{\text{eq}}\left( \text{E} \right)}{\text{K}_{\text{eq}}\left( \text{ES} \right)}\text{k}_{- 1}$$Expression for reaction rates at short times: As discussed in the main text, since k~E~ + k~-E~, k~ES~ + k~-ES~ $\ll$ k~cat,E~, k~-1~ two limiting cases are considered. For short times, t $\ll$ 1/(k~E~+k~-E~), 1/(k~ES~+k~-ES~) the two forms of the enzyme E and E^∗^ present at the start of the reaction are effectively converting the substrate independently. It is assumed that the equilibrium between E and E^∗^ has been reached by the start of the experiment and it not perturbed initially, thus the population of E, p~E~, immediately before adding substrate is given by,$$\text{K}_{\text{eq}}\left( \text{E} \right) + 1 = \frac{\left\lbrack \text{E}^{\ast} \right\rbrack}{\left\lbrack \text{E} \right\rbrack} + \frac{\left\lbrack \text{E} \right\rbrack}{\left\lbrack \text{E} \right\rbrack} = \frac{1}{\text{p}_{\text{E}}}$$The overall rate is given by$$\text{v}_{0} = - \frac{\text{dS}}{\text{dt}} = \left\lbrack \text{ES} \right\rbrack\text{k}_{\text{cat},\text{E}} + \left\lbrack {\text{E}^{\ast}\text{S}} \right\rbrack\text{k}_{\text{cat},E \ast}$$Assuming steady state for both ES and E^∗^S, that is, d\[ES\]/dt = 0 and d\[E^∗^S\]/dt = 0 gives:$$\text{v}_{0} = \frac{\text{E}_{0}}{1 + \text{K}_{\text{eq}}\left( \text{E} \right)}\frac{\text{k}_{\text{cat},\text{E}} + \text{k}_{\text{cat},\text{E} \ast}\text{K}_{\text{eq}}\left( \text{E} \right)}{{{1 + \text{K}_{\text{M},\text{E}}}/\left\lbrack \text{S} \right\rbrack} + {\text{K}_{\text{M},\text{E} \ast}/\left\lbrack \text{S} \right\rbrack} + \text{K}_{\text{M},\text{E}}{\text{K}_{\text{M},\text{E} \ast}/\left\lbrack \text{S} \right\rbrack^{2}}}$$where$$\text{K}_{\text{M},\text{E}} = \frac{\text{k}_{\text{cat},\text{E}} + \text{k}_{- 1}}{\text{k}_{1}}\mspace{9mu}\mspace{9mu}\mspace{9mu}\mspace{9mu}\mspace{9mu}\mspace{9mu}\mspace{9mu}\mspace{9mu}\mspace{9mu}\text{K}_{\text{M},E \ast} = \frac{\text{k}_{\text{cat},\text{E} \ast} + {{\text{k}_{- 1}\text{K}_{\text{eq}}\left( \text{E} \right)}/{\text{K}_{\text{eq}}\left( \text{ES} \right)}}}{\text{k}_{1}}$$It is noted that for short times the initial rate v~0~ cannot be cast in a form of apparent Michaelis-Menten parameters. Still, when the kinetic parameters and initial substrate concentration are known, the limiting initial rate can be calculated using the equation above as shown in [Figure 2](#fig2){ref-type="fig"} (dotted lines).

Expression for apparent Michaelis--Menten parameters for long times: For times t $\gg$ 1/(k~E~+k~-E~), 1/(k~ES~+k~-ES~) an equilibrium between E, E^∗^, ES and E^∗^S is reached and apparent Michaelis-Menten parameters can be calculated. Since equilibrium is assumed to have been reached:$$\text{K}_{\text{eq}}\left( \text{E} \right) = \frac{\left\lbrack \text{E}^{\ast} \right\rbrack}{\left\lbrack \text{E} \right\rbrack}\mspace{9mu}\mspace{9mu}\mspace{9mu}\mspace{9mu}\mspace{9mu}\text{and~}\mspace{9mu}\mspace{9mu}\mspace{9mu}\text{K}_{\text{eq}}\left( \text{ES} \right) = \frac{\left\lbrack {\text{E}^{\ast}\text{S}} \right\rbrack}{\left\lbrack \text{ES} \right\rbrack}$$The total enzyme concentration, \[E\]~0~, is given by:$$\left. \left\lbrack \text{E} \right\rbrack_{0} = \left\lbrack \text{E} \right\rbrack + \left\lbrack \text{ES} \right\rbrack + \left\lbrack \text{E}^{\ast} \right\rbrack + \left\lbrack {\text{E}^{\ast}\text{S}} \right\rbrack\mspace{9mu}\mspace{9mu}\mspace{9mu}\mspace{9mu}\mspace{9mu}\mspace{9mu}\mspace{9mu}\Rightarrow \right.$$$$\left\lbrack \text{E} \right\rbrack = \frac{\left\lbrack \text{E} \right\rbrack_{0} - \left\lbrack \text{ES} \right\rbrack\left( {1 + \text{K}_{\text{eq}}\left( \text{ES} \right)} \right)}{1 + \text{K}_{\text{eq}}\left( \text{E} \right)}$$and assuming steady state for ES and E^∗^S gives:$$\text{v}_{0} = \frac{\text{k}_{\text{cat},\text{E}}\left\lbrack \text{E} \right\rbrack_{0}\left( {1 + \text{K}_{\text{eq}}\left( \text{ES} \right)\frac{\text{k}_{\text{cat},\text{E}^{\ast}}}{\text{k}_{\text{cat},\text{E}}}} \right)\ }{1 + \text{K}_{\text{eq}}\left( \text{ES} \right) + \left( {1 + \text{K}_{\text{eq}}\left( \text{E} \right)} \right)\frac{\text{K}_{\text{M},\text{E}}}{\left\lbrack \text{S} \right\rbrack}}$$where the apparent Michaelis-Menten parameters are:$$\text{K}_{\text{M},\text{app}} = \text{K}_{\text{M},\text{E}}\frac{1 + \text{K}_{\text{eq}}\left( \text{E} \right)}{1 + \text{K}_{\text{eq}}\left( \text{ES} \right)}$$$$\text{k}_{\text{cat},\text{app}} = \text{k}_{\text{cat},\text{E}}\frac{1 + \text{K}_{\text{eq}}\left( \text{ES} \right)\frac{\text{k}_{\text{cat},\text{E}^{\ast}}}{\text{k}_{\text{cat},\text{E}}}}{1 + \text{K}_{\text{eq}}\left( \text{ES} \right)}$$It should be noted that these apparent parameters are only valid after equilibrium has fully been reached (dashed lines in [Figure 2](#fig2){ref-type="fig"}).

### Small-Angle Light Scattering (SAXS) {#sec4.4.9}

Purified CoREST ternary complex was concentrated to 1 mg/ml before analysis. Data were collected at Diamond Light Source small angle scattering B21 beam line (Didcot, Oxford, UK). The datasets were analyzed using ScÅtter ([@bib19]). A structural model based on the crystal structure of crystal structures of HDAC1:MTA1 (PDB: [4BKX](pdb:4BKX){#intref0120}) and LSD1:RCOR1 (PDB: [2V1D](pdb:2V1D){#intref0125}) was calculated using CORAL ([@bib32]). The comparisons of theoretical scattering curves and the experimental datasets were performed using CRYSOL ([@bib43]). Data collection and analysis details are described in supplementary material [Table S7](#mmc1){ref-type="supplementary-material"}.

### Chemical cross-linking mass spectrometry {#sec4.4.10}

Isotopically-coded NHS-activated ester cross-linker CBDPSS was used to cross-link the protein sample. Purified CoREST complex was buffer exchanged into cross-linking buffer (50 mM HEPES and 50 mM potassium acetate) and then concentrated to 1 mg/ml. Protein was mixed with 0.2-10 mM of CBDPSS in a v/v ratio of 1:1. Reaction was performed at room temperature for 1 hour and stopped with a final concentration of 40 mM (NH~4~)~2~CO~3~. Cross-linked sample were analyzed by SDS-PAGE. The gel bands corresponding to the cross-linked complex were cut and analyzed by LC-MS. Cross-linked peptides were identified using the xQuest ([@bib26]).

### Histone expression and purification {#sec4.4.11}

The full-length *Xenopus* histones (H2A, H2B, H3(K4C) or H4) in a pET expression vector were expressed in BL21(DE3)pLysS *E. coli* and induced with IPTG (0.2 mM) at 37°C for 3 h. Cells were pelleted and resuspended with histone wash buffer (50 mM Tris pH 7.5, 100 mM NaCl, 1 mM EDTA and 1% Triton X-100) followed by lysed with French press. The inclusion bodies were pelleted, washed with histone wash buffer without Triton X-100, and then resuspended in histone unfolding buffer (6 M guanidinium chloride, 20 mM Tris pH 7.5 and 10 mM DTT) and then buffer exchanged into IEX buffer (7 M urea, 10 mM Tris pH 7.8, 1 mM EDTA and 5 mM BME). The histone was purified by tandem HiTrap Q-SP columns with a NaCl gradient from 0 mM to 500 mM with IEX buffer. After dialysis against water, histone proteins were lyophilized to dryness.

### Preparation of propargylamine-containing mimic of dimethyl Lys4 histone H3 {#sec4.4.12}

The histone H3 (K4C) protein was dissolved in reaction buffer (4 M guanidinium chloride, 1 M HEPES pH 7.8, 10 mM L-Met), and DTT was added to a final concentration of 10 mM. The mixture was heated at 37°C for 1 h and diluted 4-fold with the reaction buffer. Next, 1-methyl-1-(prop-2-ynyl)aziridinium chloride was added to a final concentration of 15 mM in an ice bath. The mixture was kept at 25°C for 20 h. The reaction was monitored by mass spectrometry and the product was purified by reversed phase HPLC with a C4 column.

### Histone octamer refolding and nucleosome reconstitution {#sec4.4.13}

The core histone proteins H2A, H2B, H3(K4C) and H4 were dissolved in unfolding buffer (7 M guanidine, 20 mM Tris pH 7.5 and 10 mM DTT) and dialyzed against high salt buffer (20 mM Tris pH 7.5, 2.0 M NaCl, 1 mM EDTA and 5 mM BME). The octamer was purified by size exclusion chromatography with a Superdex 200 column. The 185 bp 601 DNA was amplified by PCR from the 601 DNA template and purified by anion exchange chromatography with a TSKgel column.

The histone octamer and DNA were mixed at a 1:1 molar ratio in high salt buffer (10 mM Tris 7.5, 2.0 M KCl, 1 mM EDTA and 1 mM DTT), and the mixture was gradually dialyzed to low salt buffer (10 mM Tris pH 7.5, 0.25 M KCl, 1 mM EDTA and 1 mM DTT) over 36 h. The nucleosomes were purified by anion exchange chromatography with TSKgel and dialyzed to 20 mM Tris pH 7.5 and 1 mM DTT. Due to the zinc ion in the CoREST complex, we did not add 1 mM EDTA to the nucleosome storage buffer.

### Structural determination of the CoREST complex using negative stain EM {#sec4.4.14}

The CoREST ternary complex was purified through a Superose 6 column and the peak fraction was concentrated and further purified in a 5%--25% sucrose density gradient (with 0%--0.1% glutaraldehyde). The sucrose density gradient was made in buffer containing 20 mM HEPES pH 7.5 and 40 mM NaCl. The gradient was manually fractionated with a fraction volume of 175 μl. The fraction containing intra-complex cross-linked sample was selected and buffer exchanged into 25 mM Tris pH 7.5, 50 mM potassium acetate and 0.5 mM TCEP.

Negative-stain grids (carbon film 400 mesh copper grid, Agar Scientific) were prepared by glow-discharging in an auto sputter coater (E5200, Quorum Technologies) for 30 s at 10 mA. 50 ng of the CoREST ternary complex was applied onto the grid and the excess liquid was blotted after 1-minute incubation. 2% uranyl acetate was used to stain the sample. The grid was visualized on a JEOL 2010F 200kV electron microscope and micrographs were taken using a Gatan Ultrascan 4000 camera at University of Warwick. 364 micrographs were collected with defocus values of −0.5 μm, −1.0 μm, −1.5 μm, and −2.0 μm. EMAN2 ([@bib44]), Relion2.1 ([@bib40]) and Cryosparc ([@bib37]) were used for data analysis.

#### Structural determination of the CoREST complex bound to synthetic site-specific nucleosome using negative stain EM {#sec4.4.14.1}

The CoREST complex was purified through Superose 6 column in buffer containing 20 mM HEPES and 50 mM NaCl. A propargylamine-containing mimic of dimethyl Lys4 histone H3 was prepared as previously described ([@bib35]). The modified histone H3 and *E. coli* Expressed H2A, H2B and H4 were then assembled with 185 bp 601 nucleosomal DNA as previously reported ([@bib49]). Interactions of the nucleosome with the CoREST complex were analyzed on a 0.7% agarose gel buffered in 0.5x TB (45 mM Tris, 45 mM boric acid). The gel was first stained with ethidium bromide and visualized using UV to analyze the DNA and, the same gel was then stained with InstantBlue to analyze the protein.

For preparing sample for negative stain, the CoREST complex was mixed with nucleosome in a molar ratio of 3:1. The mixture was incubated at room temperature for 2 hours and purified through a Superdex 200 (3.2/300) column with a fractionation size of 50 μl. The sample from each fraction was analyzed on a 0.7% agarose gel in 0.5x TB buffer. The gel was stained with ethidium bromide and visualized using UV. The fraction that contained the highest percentage of nucleosome:LHC in a 1:1 complex was selected, and cross-linked with 0.01% glutaraldehyde. 5 μl of cross-linked sample was applied on glow discharged grid (carbon film 400 mesh copper grid, Agar Scientific). The sample was stained with 2.5% uranyl acetate for 1 min. The grid was visualized using a Talos F200C 200kV electron microscope at the MRC Toxicology Unit (Leicester). 384 micrographs were collected using a Ceta 16M CMOS camera (total electron dose 30-40 e-/Å^2^ for 1 s exposure). Micrographs were collected using FEI EPU software with defocus values of −1.0 μm, −1.5 μm, and −2.0 μm. Relion3.0 ([@bib57]) was used for data analysis.

### Cryo Electron Microscopy sample preparation and imaging {#sec4.4.15}

#### Preparation of cross-linked protein sample {#sec4.4.15.1}

The CoREST ternary complex was gel filtrated in buffer containing 25 mM HEPES and 50 mM potassium chloride. Protein was then concentrated to 0.6 mg/ml or 0.8 mg/ml and mixed with glutaraldehyde (0.15%) or BS^3^ (4 mM) in a v/v ratio of 1:1. Reactions were performed at room temperature for 5 minutes and stopped with a final concentration of 50 mM Tris.

#### Preparation of vitrified specimen {#sec4.4.15.2}

3 μl of 0.03 mg/ml sample was applied on the graphene oxide coated Quantifoil 300 mesh Au R1.2/1.3 grid. The sample was blotted for 4 s after 30 s waiting time (4°C, 100% humidity) with a blot force of 10 and then plunged into liquid ethane (FEI Vitrobot).

#### Data acquisition and processing {#sec4.4.15.3}

Datasets were collected on Titan Krios microscope operated at 300 kV equipped with a Gatan Quantum energy filter, a Gatan K2 summit direct electron camera (Gatan) and a Volta phase plate (Thermo Fisher Scientific). Movies were taken in EFTEM with a slit width of 20 eV and at a nominal magnification of 105kx corresponding to a calibrated pixel size of 1.4 Å at the specimen level. Each movie comprises 36 sub-frames with a total dose of 32 e-/Å^2^, exposure time was 14 s with a dose rate of 4.47 e-/pixel/s on the detector. Data acquisition was done using FEI EPU software at −0.5 μm defocus. For data acquisition without the Volta phase plate, movies were taken at a nominal magnification of 130kx corresponding to a calibrated pixel size of 1.08 Å at the specimen level. Each movie comprises 48 sub-frames with a total dose of 39 e-/Å^2^, exposure time was 12 s with a dose rate of 3.857 e-/pixel/s on the detector. Data acquisition was done using FEI EPU software at −3.3 μm, −3.0 μm, −2.7 μm and −2.4 μm defocus. The frame images of each micrograph were aligned and averaged for correction of beam-induced drift using MotionCor2 ([@bib55]). The local motion within a micrograph was corrected using 5 × 5 patches without dose-weighting. The defocus values of the micrographs were measured by Gctf-v1.06 ([@bib54]). SPHIRE-crYOLO was used to pick particles ([@bib45]). Picked particles were then analyzed and 3D model were generated using Relion3.0 ([@bib57]).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Experimental Replicates and Quantification {#sec4.5.1}

All data are represented as SEM (standard error of the mean). There are 3 experimental replicates.

### Statistical Analysis {#sec4.5.2}

All data are presented as mean ± SEM and analyzed using Prism (Graphpad). Student's t test was used for single variable comparison between two groups. Data are presented as ± SEM.

P values are shown in the form: ^∗∗∗^ p \< 0.001, or ^∗∗∗∗^ p \< 0.0001.

Data and Code Availability {#sec4.6}
--------------------------

The SAXs data is available from SASDB: SASDH45. The EM map of negative stained CoREST complex, cryoEM map of glutaraldehyde crosslinked CoREST complex, cryoEM map of BS^3^ crosslinked CoREST complex (open and closed) and negative stain map of the CoREST:nucleosome complex are available from EMDB: EMD-10626, EMDB: EMD-10627, EMDB: EMD-10628, EMDB: EMD-10629, EMDB: EMD-10630. Unique materials are available from the authors.

FuDA is available from: <https://www.ucl.ac.uk/hansen-lab/>.
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